An announcement from Vicore Pharma Holding AB ( ($SE:VICO) ) is now available. Vicore Pharma Holding AB announced a directed share issue to raise ...

Patent covers brilaroxazine use for treating Pulmonary Fibrosis-Similar patents have also been granted in key markets around the world ...

Angiotensin-converting enzyme (ACE) inhibitor therapy may reduce all-cause mortality in idiopathic pulmonary fibrosis (IPF) but not in COPD.

Oncology program advancing with data expected in the fourth quarter 2025BEACON-IPF close out activities to be completed in ...

New data builds on prior results, highlights LTI-03's differentiated approach, and supports the ongoing global Phase 2 RENEW ...

The findings are part of a new wave of research that uses artificial intelligence (AI) to hasten scientific discovery. IPF is marked by declining lung function and eventual respiratory failure. It ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Gersten: I've ...

SOUTH SAN FRANCISCO, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics ...

UBS Global Healthcare Conference 2025 November 10, 2025 9:30 AM ESTCompany ParticipantsPatrick Poisson - Executive ...

AI transforms healthcare by enhancing disease detection, patient care and hospital efficiency but requires careful implementation to ensure equity and effectiveness. Managed Healthcare Executive ...

A biomarker panel for IPF may identify RA patients at higher risk for ILD, supporting biological overlap between IPF and ...

Please provide your email address to receive an email when new articles are posted on . Saracatinib appeared to be “equal or superior” in stopping fibrotic responses compared with two FDA-approved ...